3.64
-0.06 (-1.62%)
| Previous Close | 3.70 |
| Open | 3.70 |
| Volume | 2,290,589 |
| Avg. Volume (3M) | 4,444,883 |
| Market Cap | 1,327,675,392 |
| Price / Sales | 201.66 |
| Price / Book | 5.98 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Operating Margin (TTM) | -1,239.23% |
| Diluted EPS (TTM) | -0.910 |
| Quarterly Revenue Growth (YOY) | -54.00% |
| Total Debt/Equity (MRQ) | 19.02% |
| Current Ratio (MRQ) | 4.07 |
| Operating Cash Flow (TTM) | -77.70 M |
| Levered Free Cash Flow (TTM) | -47.04 M |
| Return on Assets (TTM) | -26.04% |
| Return on Equity (TTM) | -79.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | AtaiBeckley Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 1.50 |
|
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.78% |
| % Held by Institutions | 31.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 2,750,000 |
| Ally Bridge Group (Ny) Llc | 31 Dec 2025 | 1,713,105 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (HC Wainwright & Co., 586.81%) | Buy |
| Median | 14.00 (284.62%) | |
| Low | 11.00 (Guggenheim, 202.20%) | Buy |
| Average | 16.67 (357.97%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 09 Mar 2026 | 14.00 (284.62%) | Buy | 3.89 |
| HC Wainwright & Co. | 02 Mar 2026 | 25.00 (586.81%) | Buy | 3.68 |
| Guggenheim | 20 Jan 2026 | 11.00 (202.20%) | Buy | 3.85 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Jan 2026 | Announcement | AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |